Canada markets closed
  • S&P/TSX

    20,230.40
    +57.05 (+0.28%)
     
  • S&P 500

    4,400.64
    -0.82 (-0.02%)
     
  • DOW

    34,930.93
    -127.59 (-0.36%)
     
  • CAD/USD

    0.7986
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    72.43
    +0.04 (+0.06%)
     
  • BTC-CAD

    49,653.96
    +561.11 (+1.14%)
     
  • CMC Crypto 200

    938.33
    +8.40 (+0.90%)
     
  • GOLD FUTURES

    1,807.70
    +8.00 (+0.44%)
     
  • RUSSELL 2000

    2,224.96
    +33.12 (+1.51%)
     
  • 10-Yr Bond

    1.2610
    +0.0270 (+2.19%)
     
  • NASDAQ futures

    14,983.75
    -27.75 (-0.18%)
     
  • VOLATILITY

    18.31
    -1.05 (-5.42%)
     
  • FTSE

    7,016.63
    +20.55 (+0.29%)
     
  • NIKKEI 225

    27,581.66
    -388.56 (-1.39%)
     
  • CAD/EUR

    0.6738
    -0.0003 (-0.04%)
     

OCGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 17, 2021 in the Class Action Filed on Behalf of Ocugen, Inc. Limited Shareholders

·2 min read

New York, New York--(Newsfile Corp. - June 23, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that the Company violated federal securities laws.

Class Period: February 2, 2021 and June 10, 2021
Lead Plaintiff Deadline: August 17, 2021
No obligation or cost to you.

Learn more about your recoverable losses in OCGN:
https://www.kleinstocklaw.com/pslra-1/ocugen-inc-loss-submission-form?id=17131&from=5

Ocugen, Inc. NEWS - OCGN NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Ocugen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Ocugen you have until August 17, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Ocugen securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the OCGN lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88442

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting